As Eastman Chemical Co (EMN) Stock Declined, Shareholder Motley Fool Wealth Management Trimmed by $9.05 Million Its Holding; As Therapeuticsmd (TXMD) Stock Declined, Greenwood Capital Associates Boosted Its Holding by $464,280

TherapeuticsMD, Inc. (NASDAQ:TXMD) Logo

Greenwood Capital Associates Llc increased its stake in Therapeuticsmd Inc (TXMD) by 89.31% based on its latest 2018Q3 regulatory filing with the SEC. Greenwood Capital Associates Llc bought 77,380 shares as the company’s stock declined 30.24% with the market. The institutional investor held 164,023 shares of the health care company at the end of 2018Q3, valued at $1.08M, up from 86,643 at the end of the previous reported quarter. Greenwood Capital Associates Llc who had been investing in Therapeuticsmd Inc for a number of months, seems to be bullish on the $1.22B market cap company. The stock decreased 0.29% or $0.01 during the last trading session, reaching $5.14. About 1.37M shares traded. TherapeuticsMD, Inc. (NYSEMKT:TXMD) has declined 28.29% since January 14, 2018 and is downtrending. It has underperformed by 28.29% the S&P500. Some Historical TXMD News: 30/05/2018 – Top 3 — #1 FDA executes a 180 on TherapeuticsMD therapy, handing it an OK – and stoking concerns about political influence $TXMD; 03/05/2018 – TherapeuticsMD 1Q Loss/Shr 11c; 03/05/2018 – THERAPEUTICSMD 1Q LOSS/SHR 11C, EST. LOSS/SHR 9.0C; 30/05/2018 – TherapeuticsMD Gets FDA Approval of TX-004HR: IMVEXXY (Estradiol Vaginal Inserts); 02/04/2018 – TherapeuticsMD Names Jane F. Barlow Independent Director to Bd of Directors; 10/04/2018 – TherapeuticsMD at Deutsche Bank Health Care Conference May 8; 30/05/2018 – FDA approves TherapeuticsMD’s hormone therapy; 30/05/2018 – TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Pro; 07/05/2018 – TherapeuticsMD at Deutsche Bank Health Care Conference Tomorrow; 11/04/2018 – TherapeuticsMD Enters Into Label Negotiations With FDA for TX-004HR

Motley Fool Wealth Management Llc decreased its stake in Eastman Chemical Co (EMN) by 97.21% based on its latest 2018Q3 regulatory filing with the SEC. Motley Fool Wealth Management Llc sold 95,277 shares as the company’s stock declined 24.97% with the market. The institutional investor held 2,730 shares of the major chemicals company at the end of 2018Q3, valued at $261,000, down from 98,007 at the end of the previous reported quarter. Motley Fool Wealth Management Llc who had been investing in Eastman Chemical Co for a number of months, seems to be less bullish one the $10.71 billion market cap company. The stock decreased 0.60% or $0.46 during the last trading session, reaching $76.44. About 509,232 shares traded. Eastman Chemical Company (NYSE:EMN) has declined 20.52% since January 14, 2018 and is downtrending. It has underperformed by 20.52% the S&P500. Some Historical EMN News: 27/04/2018 – EASTMAN CHEMICAL CO EMN.N : UBS RAISES TARGET PRICE TO $119 FROM $115; 26/04/2018 – EASTMAN CHEMICAL 1Q ADJ EPS $2.23, EST. $2.09; 27/04/2018 – EASTMAN SEES 1H EPS ‘MODESTLY HIGHER’ THAN 2H; 20/04/2018 – DJ Eastman Chemical Company, Inst Holders, 1Q 2018 (EMN); 16/05/2018 – Kara Eastman declared victory in Nebraska’s 2nd Congressional District Democratic primary after running to the left of former Rep. Brad Ashford; 09/05/2018 – EASTMAN REPORTS PLANNED EXPANSION OF COPOLYESTER PRODUCTION; 08/05/2018 – Brad Lich to address the Goldman Sachs Basic Materials Conference; 02/04/2018 – Eastman Recognized as an ENERGY STAR® Partner of the Year for the Seventh Time; 09/05/2018 – Eastman Chemical: New Expansion to Be Complete in 3Q; 26/04/2018 – EASTMAN CHEMICAL SEES FY ADJ EPS +10% TO +14%

Another recent and important Eastman Chemical Company (NYSE:EMN) news was published by Seekingalpha.com which published an article titled: “Dividends Are The Only Defense In This Turbulent Market – Seeking Alpha” on December 21, 2018.

Motley Fool Wealth Management Llc, which manages about $130.00 million and $1.48B US Long portfolio, upped its stake in Fast Retailing Co Ltd (FRCOY) by 7,300 shares to 201,243 shares, valued at $10.19 million in 2018Q3, according to the filing. It also increased its holding in Guggenheim Bulletshares 2018 Corporate Bond Etf by 68,713 shares in the quarter, for a total of 1.63M shares, and has risen its stake in Guggenheim Bulletshares 2020 Corporate Bond Etf.

Among 19 analysts covering Eastman Chemical Company (NYSE:EMN), 11 have Buy rating, 2 Sell and 6 Hold. Therefore 58% are positive. Eastman Chemical Company had 72 analyst reports since July 30, 2015 according to SRatingsIntel. Jefferies maintained Eastman Chemical Company (NYSE:EMN) on Monday, August 28 with “Buy” rating. Jefferies maintained the shares of EMN in report on Friday, March 9 with “Buy” rating. The firm has “Buy” rating given on Tuesday, February 6 by Jefferies. Credit Agricole downgraded the shares of EMN in report on Monday, May 2 to “Underperform” rating. The rating was maintained by Citigroup on Monday, October 29 with “Neutral”. Goldman Sachs upgraded the shares of EMN in report on Thursday, September 28 to “Buy” rating. The firm earned “Buy” rating on Thursday, August 24 by KeyBanc Capital Markets. Barclays Capital maintained it with “Equal-Weight” rating and $108 target in Monday, February 5 report. Deutsche Bank maintained it with “Buy” rating and $85 target in Monday, May 2 report. The company was upgraded on Wednesday, December 26 by Standpoint Research.

Analysts await Eastman Chemical Company (NYSE:EMN) to report earnings on January, 31 after the close. They expect $1.63 EPS, up 0.62% or $0.01 from last year’s $1.62 per share. EMN’s profit will be $228.27M for 11.72 P/E if the $1.63 EPS becomes a reality. After $2.34 actual EPS reported by Eastman Chemical Company for the previous quarter, Wall Street now forecasts -30.34% negative EPS growth.

Investors sentiment decreased to 0.78 in Q3 2018. Its down 0.36, from 1.14 in 2018Q2. It dropped, as 48 investors sold EMN shares while 221 reduced holdings. 59 funds opened positions while 151 raised stakes. 111.12 million shares or 2.12% less from 113.52 million shares in 2018Q2 were reported. Caisse De Depot Et Placement Du Quebec invested in 0% or 6,595 shares. State Of New Jersey Common Pension Fund D stated it has 5,000 shares or 0% of all its holdings. Davenport And Communication Limited Liability Corporation has 0.01% invested in Eastman Chemical Company (NYSE:EMN) for 8,046 shares. Aspiriant Limited Company reported 2,364 shares. Gotham Asset Management Limited Co reported 0.02% of its portfolio in Eastman Chemical Company (NYSE:EMN). Chilton Capital Mngmt Ltd Com owns 0.11% invested in Eastman Chemical Company (NYSE:EMN) for 14,269 shares. Telos Cap Mgmt Inc holds 0.83% in Eastman Chemical Company (NYSE:EMN) or 26,996 shares. South Dakota Investment Council reported 0.62% in Eastman Chemical Company (NYSE:EMN). Pennsylvania owns 2,715 shares. First Natl Bank Of Mount Dora has 1.45% invested in Eastman Chemical Company (NYSE:EMN) for 35,241 shares. 7,152 are owned by Wagner Bowman Management Corp. Mitsubishi Ufj Secs, a Japan-based fund reported 160 shares. Conning Incorporated has 0.01% invested in Eastman Chemical Company (NYSE:EMN). Ing Groep Nv invested in 0% or 2,410 shares. Vident Investment Advisory Lc has invested 0.01% in Eastman Chemical Company (NYSE:EMN).

Since July 31, 2018, it had 1 insider buy, and 2 selling transactions for $1.38 million activity. 3,523 Eastman Chemical Company (NYSE:EMN) shares with value of $364,912 were sold by BOLDEA LUCIAN. RAISBECK DAVID W had bought 13,500 shares worth $988,335 on Friday, December 7.

More notable recent TherapeuticsMD, Inc. (NASDAQ:TXMD) news were published by: Benzinga.com which released: “TherapeuticsMD (NASDAQ:TXMD) Announces FDA Approval Of IMVEXXY — For Real This Time – Benzinga” on May 30, 2018, also Nasdaq.com with their article: “TXMD Crosses Above Key Moving Average Level – Nasdaq” published on August 24, 2018, Nasdaq.com published: “Here’s Why TherapeuticsMD Inc Jumped Today – Nasdaq” on June 05, 2018. More interesting news about TherapeuticsMD, Inc. (NASDAQ:TXMD) were released by: Finance.Yahoo.com and their article: “Jim Cramer Weighs In On Palo Alto, Blackstone And More – Yahoo Finance” published on December 21, 2018 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 10/29/2018: RKDA, TXMD, PFE, NVS – Nasdaq” with publication date: October 29, 2018.

Greenwood Capital Associates Llc, which manages about $970.61M and $459.05 million US Long portfolio, decreased its stake in Select Sector Spdr (XLE) by 18,154 shares to 42,050 shares, valued at $3.19 million in 2018Q3, according to the filing. It also reduced its holding in Suntrust Banks Inc (NYSE:STI) by 21,335 shares in the quarter, leaving it with 66,807 shares, and cut its stake in Select Sector Spdr (XLK).

Since August 21, 2018, it had 1 insider buy, and 25 insider sales for $25.77 million activity. 182,800 shares were sold by Bernick Brian, worth $866,746 on Monday, November 19. $1.27 million worth of TherapeuticsMD, Inc. (NASDAQ:TXMD) shares were sold by Milligan John C.K. IV. On Thursday, October 25 Finizio Robert G sold $972,072 worth of TherapeuticsMD, Inc. (NASDAQ:TXMD) or 184,000 shares. Another trade for 4,000 shares valued at $22,100 was bought by Thompson Tommy G.

Investors sentiment increased to 1.8 in Q3 2018. Its up 0.56, from 1.24 in 2018Q2. It is positive, as 12 investors sold TXMD shares while 28 reduced holdings. 28 funds opened positions while 44 raised stakes. 174.81 million shares or 12.04% more from 156.02 million shares in 2018Q2 were reported. Perceptive Advisors Limited Liability Company reported 1.50 million shares. Amer International Group, a New York-based fund reported 121,202 shares. Sta Wealth Management Ltd Liability Co holds 0.03% of its portfolio in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 13,873 shares. Hanson Mcclain holds 500 shares. D E Shaw Com accumulated 544,613 shares or 0% of the stock. Citigroup invested in 0% or 8,045 shares. Raymond James Trust Na invested in 0.01% or 17,041 shares. Stratos Wealth Ptnrs Ltd reported 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Geode Cap Mgmt Ltd Liability invested in 2.02 million shares. Stevens Mngmt LP has 15,330 shares for 0% of their portfolio. Td Asset Inc invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). First Advisors Limited Partnership has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Ubs Asset Americas Inc has invested 0% in TherapeuticsMD, Inc. (NASDAQ:TXMD). Ameritas Inv Prtnrs owns 0% invested in TherapeuticsMD, Inc. (NASDAQ:TXMD) for 12,961 shares. 1492 Cap Management Ltd Liability Co owns 368,049 shares or 1.57% of their US portfolio.

Among 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TherapeuticsMD had 6 analyst reports since September 21, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, December 8 with “Buy”. The rating was initiated by Oppenheimer on Tuesday, November 22 with “Outperform”. The rating was reinitiated by Jefferies with “Buy” on Tuesday, November 22. Jefferies maintained it with “Buy” rating and $15.0 target in Monday, September 21 report. Stifel Nicolaus maintained the shares of TXMD in report on Tuesday, December 8 with “Buy” rating.

Eastman Chemical Company (NYSE:EMN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.